Blood Reviews最新文献_第2页

Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management. 急性早幼粒细胞白血病辨证研究进展：从机制到治疗。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-08-26 DOI: 10.1016/j.blre.2026.101419

Shuang Han, Yiqun Zhao, Ying Su, Yingxin Wang, Dongxia Wang, Xue Xing

引用次数: 0

Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies. 真性红细胞增多症中靶向hepcidin-铁转运蛋白轴：克隆定向治疗的补充方法。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-08-26 DOI: 10.1016/j.blre.2026.101420

Alessandro Costa, Federica Pilo, Massimo Breccia

{"title":"Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.","authors":"Alessandro Costa, Federica Pilo, Massimo Breccia","doi":"10.1016/j.blre.2026.101420","DOIUrl":"https://doi.org/10.1016/j.blre.2026.101420","url":null,"abstract":"<p><p>Polycythemia vera (PV) is a clonal myeloproliferative neoplasm in which erythrocytosis, although driven by constitutive JAK2 signaling, remains dependent on iron availability. This dependency provides a rationale for therapeutic targeting of the hepcidin-ferroportin axis, whose modulation induces functional iron restriction and constrains erythropoiesis. The hepcidin mimetic rusfertide has shown durable hematocrit control and marked reduction of phlebotomy requirements across phase 2 and phase 3 studies, with predictable changes in systemic iron markers. However, current evidence is largely based on surrogate hematologic endpoints, and whether iron-directed strategies reduce thrombotic risk or modify disease trajectory remains undefined. Within this framework, iron metabolism can be viewed as a downstream, regulatable determinant of erythropoietic output, distinct from but integrated with clonal and inflammatory signaling. This review summarizes biological and clinical evidence on iron homeostasis in PV, focusing on the hepcidin-ferroportin axis and its integration with clone-directed therapies.</p>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101420"},"PeriodicalIF":7.2,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148842156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How artificial intelligence may solve diagnostic and prognostic challenges in classic Hodgkin lymphoma 人工智能如何解决经典霍奇金淋巴瘤的诊断和预后挑战

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-04-10 DOI: 10.1016/j.blre.2026.101390

Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone

{"title":"How artificial intelligence may solve diagnostic and prognostic challenges in classic Hodgkin lymphoma","authors":"Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone","doi":"10.1016/j.blre.2026.101390","DOIUrl":"10.1016/j.blre.2026.101390","url":null,"abstract":"<div><div>Classic Hodgkin lymphoma (cHL) is highly curable, yet its diagnosis, risk stratification, and response assessment remain susceptible to significant uncertainty. Hodgkin Reed–Sternberg (HRS) cells are rare and embedded within a heterogeneous inflammatory tumor microenvironment (TME), creating diagnostic ambiguity in small biopsies. Moreover, FDG PET/CT shows notable inter-reader and inter-institutional variability. At the same time, key biologic determinants of outcome, including TME architecture and immune evasion mechanisms, have proven challenging to standardize as clinically actionable biomarkers. This narrative review synthesizes emerging evidence on the use of artificial intelligence (AI) to address these limitations across three domains: (i) histopathologic diagnosis and refinement of gray-zone entities, (ii) PET/CT-based prognostication and response assessment, and (iii) computational interrogation of the TME. We summarize retrospective and proof-of-concept studies leveraging digital pathology, radiomics, and multimodal modeling, with attention to dataset characteristics, validation strategies, and clinical endpoints. Across applications, most AI models are trained on single-center retrospective cohorts, lack external validation, and exhibit substantial risk of bias, limiting conclusions about generalizability and clinical utility. Current evidence indicates that AI is most advanced as a decision-support and standardization tool—facilitating HRS cell quantification, harmonizing PET-derived features, and enabling reproducible spatial immune profiling—rather than as an autonomous diagnostic or prognostic system. Real-world translation will require large multicenter datasets, clearly defined clinical use-cases, rigorous bias and performance assessment, external validation, and adherence to emerging reporting frameworks (TRIPOD-AI, QUADAS-AI, PROBAST-AI). We outline practical steps needed to progress AI in cHL from technical feasibility toward clinically reliable implementation.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101390"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet transfusion guidelines for thrombocytopenic patients in non-surgical and non-traumatic care settings: A systematic review and methodological quality assessment 血小板减少患者在非手术和非创伤性护理环境中的血小板输注指南：系统回顾和方法学质量评估。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-03-10 DOI: 10.1016/j.blre.2026.101388

Yana Criel, Hendrik B. Feys, Emmy De Buck, Philippe Vandekerckhove, Timothy Devos, Peter Vandenberghe, Hans Van Remoortel

{"title":"Platelet transfusion guidelines for thrombocytopenic patients in non-surgical and non-traumatic care settings: A systematic review and methodological quality assessment","authors":"Yana Criel, Hendrik B. Feys, Emmy De Buck, Philippe Vandekerckhove, Timothy Devos, Peter Vandenberghe, Hans Van Remoortel","doi":"10.1016/j.blre.2026.101388","DOIUrl":"10.1016/j.blre.2026.101388","url":null,"abstract":"<div><div>This systematic review aimed to identify clinical practice guidelines (CPGs) for platelet transfusion in non-surgical and non-traumatic care settings, and appraise their methodological quality. We searched three databases and eight grey literature sources for CPGs published between 2015 and 2025. Methodological characteristics of the literature review and guideline development process were charted. Data on the targeted population, transfusion indication, and the direction and strength of the recommendations were extracted. CPG methodological quality was assessed using the AGREE II Rigour of Development domain. We identified 30 CPGs, including 89 recommendations. Platelet transfusion recommendations were summarized in interactive evidence maps. These tools can aid clinicians seeking evidence-based guidance to support clinical decision making, and highlight priorities for future research. AGREE II assessment indicated good to poor methodological quality of the included CPGs. This work underscores the importance of applying a rigorous and transparent methodology to ensure the development of reliable CPGs.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101388"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147476248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure 急性髓性白血病的免疫治疗：抗体、TriKEs和car在艰难的治愈之路上。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-04-18 DOI: 10.1016/j.blre.2026.101391

B. Adhikari, M.R. Litzow, A.L. Dias

引用次数: 0

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group 成人急性髓细胞白血病和早幼粒细胞白血病的抗菌、抗真菌和抗病毒预防和疫苗接种策略：GIMEMA小组的专家小组共识

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-06-20 DOI: 10.1016/j.blre.2026.101412

Francesco Marchesi, Corrado Girmenia, Enrico Maria Trecarichi, Alfonso Piciocchi, Alessandro Busca, Anna Candoni, Chiara Cattaneo, Mario Delia, Maria Ilaria Del Principe, Luana Fianchi, Giuseppe Gentile, Nicola Stefano Fracchiolla, Mario Tumbarello, Marco Vignetti, Adriano Venditti, Livio Pagano

{"title":"Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group","authors":"Francesco Marchesi, Corrado Girmenia, Enrico Maria Trecarichi, Alfonso Piciocchi, Alessandro Busca, Anna Candoni, Chiara Cattaneo, Mario Delia, Maria Ilaria Del Principe, Luana Fianchi, Giuseppe Gentile, Nicola Stefano Fracchiolla, Mario Tumbarello, Marco Vignetti, Adriano Venditti, Livio Pagano","doi":"10.1016/j.blre.2026.101412","DOIUrl":"10.1016/j.blre.2026.101412","url":null,"abstract":"<div><div>Infections are a leading cause of morbidity, mortality, and treatment delays in AML and APL. While international guidelines emphasize intensive chemotherapy, they often overlook less intensive regimens, rely on outdated data, and ignore rising MDR infections. A GIMEMA survey across Italian centers revealed significant heterogeneity in antimicrobial prophylaxis, and vaccination practices. An expert panel reviewed 2012–2025 English literature with focus on infections via Delphi/nominal group methods, achieving ≥70% consensus. Prophylaxis with fluoroquinolones showed low agreement (28%) for intensive chemotherapy and venetoclax-based regimens due to no survival benefit, MDR pressure and microbiota disruption; not recommended for low-intensity/palliative care. Posaconazole is advised for intensive chemotherapy with or without FLT3 inhibitors, venetoclax-based regimens, HMA with or without ivosidenib (first 4 cycles), but not APL/palliative care. Antiviral prophylaxis is recommended for APL receiving arsenic trioxide; limited evidence elsewhere. The panel supports universal pneumococcal, influenza, SARS-CoV-2 and herpes zoster vaccination. Overall, these consensus statements aim to harmonize practice and highlight key areas requiring specifically designed prospective studies.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101412"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148334610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility 环境暴露与多发性骨髓瘤风险：流行病学关联和机制合理性的当代回顾。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-04-18 DOI: 10.1016/j.blre.2026.101392

Maria Victoria del Rosal, Mike Z. He, Sundar Jagannath, Samir Parekh, Itai Kloog, Manish Arora, Santiago Thibaud

{"title":"Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility","authors":"Maria Victoria del Rosal, Mike Z. He, Sundar Jagannath, Samir Parekh, Itai Kloog, Manish Arora, Santiago Thibaud","doi":"10.1016/j.blre.2026.101392","DOIUrl":"10.1016/j.blre.2026.101392","url":null,"abstract":"<div><div>Despite major advances in the molecular characterization and treatment of multiple myeloma (MM), the factors driving disease onset remain poorly defined. Environmental influences represent a critical but underexplored component. Epidemiologic studies have associated a range of environmental and occupational exposures with increased MM risk, including pesticides, dioxins, and combustion byproducts, with experimental data supporting biologic plausibility through mechanisms such as oxidative stress, DNA damage, and aryl hydrocarbon receptor signaling. However, the available evidence is heterogeneous and largely associative, limiting causal inference. In this review, we synthesize current epidemiologic and mechanistic evidence linking environmental exposures to MM risk. We also highlight key methodological gaps and future directions, including the need for more precise exposure assessment, biospecimen-linked cohorts, and integrative studies that connect environmental data with disease biology.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101392"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147730732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PRISMA-based systematic review on iron stores in repeat blood donors. 基于prisma的重复献血者铁储存的系统评价。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-06-23 DOI: 10.1016/j.blre.2026.101411

Javiera Benitez-Navarro, Constanza Sanhueza-Andrade, Carolina Figueroa, Juan Alejandro Sepulveda, Alejandra Sandoval-Borquez, Jessica Pino-Reyes

{"title":"PRISMA-based systematic review on iron stores in repeat blood donors.","authors":"Javiera Benitez-Navarro, Constanza Sanhueza-Andrade, Carolina Figueroa, Juan Alejandro Sepulveda, Alejandra Sandoval-Borquez, Jessica Pino-Reyes","doi":"10.1016/j.blre.2026.101411","DOIUrl":"10.1016/j.blre.2026.101411","url":null,"abstract":"<div><div>Repeat blood donation may progressively reduce iron stores, although the clinical relevance of biochemical iron depletion in otherwise healthy donors remains debated. This PRISMA-based systematic review and meta-analysis evaluated iron depletion among repeat whole-blood donors and explored factors associated with prevalence estimates. Sixteen studies were included in the qualitative synthesis, and 15 contributed to meta-analyses. The pooled prevalence of iron deficiency, associated with serum ferritin measurement, among regular donors was 14.26% (95% CI: 12.50–16.23). Female donors showed a higher pooled prevalence than male donors, and meta-regression identified sex and serum ferritin cut-off values as significant determinants of prevalence, whereas donation frequency was not independently associated. These findings indicate that iron depletion is common among repeat donors but highly dependent on case definitions and donor characteristics. Serum ferritin testing may support risk stratification, but universal screening should be balanced against feasibility, donor-centered outcomes, and local resources, particularly in low and middle income settings.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101411"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148347527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Lebanese national patient blood management guidelines: A new page in the medical practice 黎巴嫩国家病人血液管理指南：在医疗实践的新一页。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-06-06 DOI: 10.1016/j.blre.2026.101410

Ali T. Taher, Rita Feghali, Hanadi Samaha, Vanda Yazbeck Karam, Samia Madi-Jebara, Mohammad Hassan Hodroj, David Atallah

{"title":"The Lebanese national patient blood management guidelines: A new page in the medical practice","authors":"Ali T. Taher, Rita Feghali, Hanadi Samaha, Vanda Yazbeck Karam, Samia Madi-Jebara, Mohammad Hassan Hodroj, David Atallah","doi":"10.1016/j.blre.2026.101410","DOIUrl":"10.1016/j.blre.2026.101410","url":null,"abstract":"<div><div>Patient blood management (PBM) is a patient-centered, systematic, evidence-based approach to improve patient outcomes by managing and preserving a patient’s own blood, while promoting patient safety and empowerment. Globally, PBM guidelines have been developed locally in several countries and societies based on the expertise and resources of each. In Lebanon, the presence of prevalent iron deficiency anemia and hemoglobinopathies, together with scarce resources and economic constraints, necessitate generating local PBM guidelines to improve outcomes, cost-effectiveness, and safety. The following guidelines were established based on the recommendations of a multidisciplinary taskforce committee of Lebanese experts from different medical specialties including hematology, obstetrics, gynecology, surgery, anesthesiology, critical care, and pediatrics. The recommendations provide key practice points for the optimization of red blood mass, minimization of blood loss, and optimization of tolerance to anemia in different settings, supported by evidence from international guidelines in the field of PBM.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101410"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148254594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The humoral pathophysiology of immune thrombocytopenia: How close are we to patient-specific disease treatment? 免疫性血小板减少症的体液病理生理学：我们离患者特异性疾病治疗还有多远？

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-03-26 DOI: 10.1016/j.blre.2026.101389

Peter A.A. Norris, Kevin D. Won, Alan H. Lazarus

{"title":"The humoral pathophysiology of immune thrombocytopenia: How close are we to patient-specific disease treatment?","authors":"Peter A.A. Norris, Kevin D. Won, Alan H. Lazarus","doi":"10.1016/j.blre.2026.101389","DOIUrl":"10.1016/j.blre.2026.101389","url":null,"abstract":"<div><div>Primary immune thrombocytopenia (ITP) is an autoimmune disease in which soluble humoral immune factors, especially anti-platelet autoantibodies, can drive thrombocytopenia by accelerating platelet clearance and impairing platelet production. The classical humoral mechanisms of ITP include autoantibodies triggering macrophage Fc gamma receptor (FcγR)-mediated phagocytosis of platelets in the spleen or liver. Work over several decades has expanded this model beyond FcγRs to include platelet desialylation with hepatic clearance pathways, complement activation with platelet-bound complement fragments, platelet apoptosis signatures, and autoantibody effects on megakaryocytes and thrombopoiesis. Specific autoantibody characteristics such as specificity, subclass, and glycosylation preferentially drive certain mechanisms which shape autoantibody pathogenicity. These mechanisms are not uniform across patients or stable over time, which likely contributes to variable responses to therapy. Here we provide an in-depth review of the evidence supporting key humoral effector pathways in ITP and outline practical opportunities and limitations for pairing therapies to inferred mechanisms. Finally, we identify knowledge gaps, including pathway-relevant biomarkers, prospective studies linking biomarkers to treatment outcomes, and gaps in the development of targeted therapies for pathways such as platelet desialylation.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101389"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0